An open-label, phase I/II safety, pharmacokinetic, and proof-of concept study of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (CRPC)

被引：0
|
作者：
Fizazi, K. [1 ]
Bono, P. [2 ]
Jones, R. H. [3 ]
Kataja, V. [4 ]
James, N. [5 ]
Garcia, J. [6 ]
Protheroe, A. [7 ]
Vuorela, A. [8 ]
Mattila, L. [8 ]
Mustonen, M. V. J. [8 ]
机构：
[1] Univ Paris, Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[2] Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland
[3] Cardiff Univ, Velindre Hosp, Cardiff CF10 3AX, S Glam, Wales
[4] Kuopio Univ Hosp, Dept Oncol, SF-70210 Kuopio, Finland
[5] Queen Elizabeth Hosp, Birmingham Univ Hosp NHS, Birmingham B15 2TH, W Midlands, England
[6] Cleveland Clin, Cleveland, OH 44106 USA
[7] Churchill Hosp, Oxford OX3 7LJ, England
[8] Orion Corp Orion Pharma, R&D, Espoo, Finland
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2853
引用
收藏
页码：S680 / S680
页数：1
相关论文
共 50 条
  • [21] An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).
    Kabbinavar, Fairooz F.
    Zomorodian, Nazy
    Rettig, Matthew
    Khan, Faraz
    Greenwald, Daniel Reif
    Davidson, Sheldon J.
    DiCarlo, Brian Anthony
    Patel, Ravi
    Pandit, Lalita
    Chandraratna, Rosh
    Sanders, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).
    Kabbinavar, Fairooz F.
    Zomorodian, Nazy
    Rettig, Matthew
    Khan, Faraz
    Greenwald, Daniel Reif
    DiCarlo, Brian
    Davidson, Sheldon J.
    Patel, Ravindranath
    Pandit, Lalita
    Chandraratna, Rosh
    Sanders, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [23] ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer
    Suzuki, Kazuhiro
    Kuss, Iris
    Smith, Matthew R.
    Fizazi, Karim
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study
    Reza, Mariana
    Jones, Robert
    Aspegren, John
    Massard, Christophe
    Mattila, Leena
    Mustonen, Mika
    Wollmer, Per
    Tragardh, Elin
    Bondesson, Eva
    Edenbrandt, Lars
    Fizazi, Karim
    Bjartell, Anders
    EUROPEAN UROLOGY FOCUS, 2016, 2 (05): : 547 - 552
  • [25] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS (CRPC)
    Verzoni, E.
    Bajetta, E.
    Giganti, M. O.
    Guadalupi, V.
    Capone, F.
    Donegani, S.
    Nicolai, N.
    Salvioni, R.
    Valdagni, R.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 278 - 278
  • [26] Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
    Slovin, S. F.
    Higano, C. S.
    Hamid, O.
    Tejwani, S.
    Harzstark, A.
    Alumkal, J. J.
    Scher, H. I.
    Chin, K.
    Gagnier, P.
    McHenry, M. B.
    Beer, T. M.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1813 - 1821
  • [27] A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
    Guadalupi, V.
    Giganti, M. O.
    Testa, I.
    Villa, S.
    Nicolai, N.
    Biasoni, D.
    Salvioni, R.
    Valdagni, R.
    Bajetta, E.
    Procopio, G.
    ANTICANCER RESEARCH, 2010, 30 (04) : 1536 - 1536
  • [28] A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Pook, David William
    Geynisman, Daniel M.
    Carles, Joan
    De Braud, Filippo G.
    Joshua, Anthony M.
    Perez-Gracia, Jose Luis
    Perez, Casilda Llacer
    Shin, Sang Joon
    Fang, Bruno
    Barve, Minal A.
    Maruzzo, Marco
    Bracarda, Sergio
    Kim, Miso
    Kerloeguen, Yannick
    Gallo, Jorge Daniel
    Maund, Sophia
    Harris, Adam
    Huang, Kuan-Chieh
    Sutaria, Dhruvitkumar S.
    Gurney, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [29] Phase II proof-of-concept study of atorvastatin in castration-resistant prostate cancer
    Rushworth, Linda K.
    Loveridge, Carolyn
    Salji, Mark
    MacLeod, Martin
    Mui, Ernest
    Sumpton, David
    Neilson, Matthew
    Hedley, Ann
    Alexander, Laura
    McCartney, Elaine
    Patel, Rachana
    Wallace, Jan
    Delles, Christian
    Jones, Rob
    Leung, Hing Y.
    BJU INTERNATIONAL, 2023, 131 (02) : 236 - 243
  • [30] ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
    Fizazi, Karim
    Shore, Neal D.
    Tammela, Teuvo L. J.
    Sarapohja, Toni
    Vuorela, Annamari
    Kuss, Iris
    Snapir, Amir
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345